Sugi Predict

Sugi Predict / Targets / HRH2

HRH2

Histamine H2 receptor · P25021 · HRH2 on Sugi Atlas →

153,979 patent compounds predicted against HRH2, 100,101 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL48086 SCHEMBL48086 0.34 16/20
Oxalic Acid Oxalic Acid (SCHEMBL48085) 0.40 15/20
SCHEMBL46979 SCHEMBL46979 0.54 14/20
Penfluridol Penfluridol (SCHEMBL93939) 1.00 6/20
SCHEMBL106768 SCHEMBL106768 0.43 6/20
SCHEMBL47984 SCHEMBL47984 0.39 6/20
Fluperamide Fluperamide (SCHEMBL120826) 0.73 5/20
SCHEMBL66633 SCHEMBL66633 0.42 5/20
SCHEMBL48203 SCHEMBL48203 0.40 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL47855) 0.40 5/20
SCHEMBL48693 SCHEMBL48693 0.39 5/20
Triflupromazine Triflupromazine (SCHEMBL44085) 0.71 4/20
Dimetacrine Dimetacrine (SCHEMBL50120) 0.59 4/20
Lidoflazine Lidoflazine (SCHEMBL79037) 0.51 4/20
Clopipazan Clopipazan (SCHEMBL120732) 0.50 4/20
SCHEMBL72415 SCHEMBL72415 0.47 4/20
SCHEMBL103263 SCHEMBL103263 0.47 4/20
SCHEMBL70723 SCHEMBL70723 0.46 4/20
SCHEMBL47911 SCHEMBL47911 0.45 4/20
SCHEMBL91873 SCHEMBL91873 0.43 4/20

Clinical trials — most relevant to HRH2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) PHASE4COMPLETED
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy PHASE4COMPLETED
A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux PHASE4WITHDRAWN
The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers PHASE4COMPLETED
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma PHASE3COMPLETED
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) PHASE3COMPLETED
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists PHASE3COMPLETED
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - PHASE3COMPLETED
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn PHASE3COMPLETED
Study of Acid Reflux in Asthma PHASE3COMPLETED
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines PHASE2COMPLETED
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria PHASE2NOT_YET_RECRUITING
Study of AG10 in Amyloid Cardiomyopathy PHASE2COMPLETED
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease PHASE2COMPLETED
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients PHASE2UNKNOWN
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function PHASE1COMPLETED
Effects of Betahistine Hydrochloride in Overweight Women PHASE1COMPLETED
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001 PHASE1COMPLETED
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease PHASE1COMPLETED
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma PHASE1COMPLETED
Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function PHASE1NOT_YET_RECRUITING
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn PHASE1COMPLETED
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers nanCOMPLETED
Gracie Diet for Gastroesophageal Reflux Disease nanACTIVE_NOT_RECRUITING
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer nanCOMPLETED
Economic Impact of Guidelines for Gastroesophageal Reflux Disease nanCOMPLETED
Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU) nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Treatment of Zollinger-Ellison Syndrome nanCOMPLETED
A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HRH2 binder may also engage these)

ProteinNameSimilarity
Q76MS7 — 1.000 Q76MS7 →
P60021 — 1.000 P60021 →
P61752 — 1.000 P61752 →
P47747 — 1.000 P47747 →
P25102 — 1.000 P25102 →
P17124 — 1.000 P17124 →
Q28997 — 0.994 Q28997 →
A0A678XMK4 — 0.993 A0A678XMK4 →
P97292 — 0.993 P97292 →
P54833 — 0.992 P54833 →
O70528 — 0.992 O70528 →
P79748 — 0.991 P79748 →
P56496 — 0.991 P56496 →
HTR4 5-hydroxytryptamine receptor 4 0.991 landscape →
P47800 — 0.991 P47800 →
Q588Y6 — 0.991 Q588Y6 →
P10608 — 0.990 P10608 →
Q4KWL2 — 0.990 Q4KWL2 →
P04274 — 0.990 P04274 →
P30966 — 0.990 P30966 →
HTR1B 5-hydroxytryptamine receptor 1B 0.989 landscape →
P79250 — 0.989 P79250 →
P97288 — 0.989 P97288 →
O42574 — 0.988 O42574 →
O42384 — 0.988 O42384 →
Q5IS72 — 0.988 Q5IS72 →
Q9N2D9 — 0.988 Q9N2D9 →
Q28044 — 0.988 Q28044 →
P30940 — 0.987 P30940 →
Q9N2B7 — 0.987 Q9N2B7 →